Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that may play an important role in colon cancer. Researchers also showed how this ...

Kirsten rat sarcoma virus oncogene homologue (KRAS) is the most frequently mutated oncogene in human cancer and is one that drives oncogenesis in up to 50% of patients with colorectal cancer. 1-6 ...

Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model. Microbiology Spectrum , 2024; DOI: 10.1128/spectrum.02720-23 ...

Advancements in precision medicine have led to new treatments aimed at KRAS mutations, including recent findings from the phase 3 CodeBreaK 300 trial. This trial supported the combination of Lumakras ...

Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine. JCO Oncol Pract 20 , 1336-1347 (2024). DOI: 10.1200/OP.23.00787 ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

KRAS is one of the oldest known oncogenes linked to cancer. KRAS mutations are especially prevalent in colorectal cancer and are associated with worse prognosis and increased resistance to treatment.

Targeting KRAS Mutations in Lung Cancer — ASCO Reading Room video analysis with thought leader James Stevenson, MD by Greg Laub , Director, Video, MedPage Today July 29, 2022 ...

How Off-the-Shelf Vaccines Targeting KRAS Mutations Differ From Personalized mRNA Vaccines. A different approach to activating immune cells has been led by surgical oncologist Vinod Balachandran, ...

KRAS is the most frequently mutated oncogene in human cancer and drives the disease in up to 50% of patients with CRC, according to BMS. The KRAS G12C mutation occurs in approximately 3% to 4% of ...